The purpose of this study is to compare two finished products of PF-07940367 in terms of the uptake into the blood stream. This study is seeking participants who are: \- Healthy male or female participants aged 18 years or older. All participants in this study will receive PF-07940367 once by mouth. The participants may receive different tablets by mouth for PF-07940367. The study will compare experiences of people receiving two different products of PF-07940367. This will help understand how much PF-07940367 is taken up into the blood for each product given. Participants will take part in the study for about 112 days. During this time, participants will have to stay onsite for 5 days. There will be up to 2 additional onsite study visits and 3 remote (telephone call) study visits.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Participants to receive a single dose of PF-07940367 product II 150 mg by mouth
Participants to receive a single dose of PF-07940367 product I 150 mg by mouth
Anaheim Clinical Trials, LLC
Anaheim, California, United States
Area under the whole blood concentration versus time curve (AUC) from time zero (pre-dose) to 336 hours (AUC336) of PF-07940367 dose to evaluate pharmacokinetic comparability of two PF-07940367 products
Time frame: 0 hours (pre-dose) to 336 hours post-PF-07940367 dose
Number of Participants With Treatment-Emergent Adverse Events (AEs)
Time frame: From baseline up to 56 days after PF-07940367 dose
Number of Participants With Clinically Significant Laboratory Abnormalities
Time frame: From baseline up to 336 hours after PF-07940367 dose
Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
Time frame: From baseline up to 96 hours after PF-07940367 dose
Number of Participants With Clinically Significant Vital Signs
Time frame: From baseline up to 336 hours after PF-07940367 dose
Maximum Observed Whole Blood Concentration (Cmax) of PF-07940367 for two PF-07940367 products
Time frame: 0 hours (pre-dose) to 336 hours post-PF-07940367 dose
Area under the whole blood concentration versus time curve (AUC) from time zero (pre-dose) to the last quantifiable concentration (AUClast) of PF-07940367 for two PF-07940367 products
Time frame: 0 hours (pre-dose) to 336 hours post-PF-07940367 dose
Time to Maximum Observed Whole Blood Concentration (Tmax) of PF-07940367 for two PF-07940367 products
Time frame: 0 hours (pre-dose) to 336 hours post-PF-07940367 dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.